Discover how selinexor's novel mechanism of action is revolutionizing treatment for penta-refractory multiple myeloma patients who have exhausted all standard therapies.
Exploring how prior alkylating therapies affect CAR T-cell therapy outcomes in multiple myeloma patients
Analysis of DREAMM-2 trial findings on belantamab mafodotin's effects on patient-reported outcomes in relapsed/refractory multiple myeloma.
Discover how E2F1 protein serves as a biomarker for selinexor resistance in multiple myeloma patients, with implications for personalized treatment approaches.